Trexquant Investment LP Decreases Stock Holdings in Dynavax Technologies Corporation $DVAX

Key Points

• Trexquant Investment LP significantly reduced its holdings in Dynavax Technologies, selling 530,987 shares and owning only 245,410 shares worth approximately $3.18 million, representing a 68.4% decrease.
• Several institutional investors have increased their stakes in Dynavax, with Caitong International Asset Management growing its position by an impressive 5,485.7%.
• Dynavax Technologies received positive attention as Wall Street Zen upgraded its rating from "hold" to "buy," with analysts citing an average price target of $24.33 for the stock.

Trexquant Investment LP trimmed its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 68.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 245,410 shares of the biopharmaceutical company's stock after selling 530,987 shares during the period. Trexquant Investment LP owned about 0.20% of Dynavax Technologies worth $3,183,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Walleye Capital LLC lifted its position in shares of Dynavax Technologies by 50,734.1% in the first quarter. Walleye Capital LLC now owns 266,879 shares of the biopharmaceutical company's stock worth $3,461,000 after buying an additional 266,354 shares in the last quarter. AlphaQuest LLC grew its stake in shares of Dynavax Technologies by 134.3% during the first quarter. AlphaQuest LLC now owns 54,920 shares of the biopharmaceutical company's stock valued at $712,000 after buying an additional 31,483 shares during the last quarter. Advantage Alpha Capital Partners LP grew its stake in shares of Dynavax Technologies by 53.2% during the first quarter. Advantage Alpha Capital Partners LP now owns 38,443 shares of the biopharmaceutical company's stock valued at $499,000 after buying an additional 13,345 shares during the last quarter. American Century Companies Inc. grew its stake in Dynavax Technologies by 11.5% in the first quarter. American Century Companies Inc. now owns 291,883 shares of the biopharmaceutical company's stock worth $3,786,000 after purchasing an additional 30,081 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its stake in Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,304 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were purchased at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the transaction, the director directly owned 35,004 shares of the company's stock, valued at approximately $378,743.28. The trade was a 12.18% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.98% of the stock is owned by company insiders.

Dynavax Technologies Stock Performance

DVAX traded down $0.31 during midday trading on Monday, hitting $9.75. 752,248 shares of the company were exchanged, compared to its average volume of 2,072,250. The company's 50 day simple moving average is $10.63 and its 200 day simple moving average is $11.19. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -21.01 and a beta of 1.24. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. Dynavax Technologies Corporation has a 1-year low of $9.22 and a 1-year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The company had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. As a group, sell-side analysts predict that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DVAX has been the topic of several research analyst reports. JMP Securities reissued a "market outperform" rating and issued a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.